Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment 5. Debunking Myths in the US Healthcare System
Top Ten Searches
aldosteronism contrast dialysis vitamin d bicarbonate arf amyloidosis hypocalcemia renal artery husYour Article Summary
See Latest ArticlesNebivolol: A third-generation beta-blocker for hypertension
Clinical Therapeutics, 05/04/09
Cheng JWM et al. - Nebivolol is a cardioselective beta-blocker that has been reported to be efficacious and well tolerated for achieving BP control in patients with hypertension. Preliminary evidence suggests a potential for reduced mortality in patients with heart failure.
Related Articles
Nebivolol in High-Risk, Obese African Americans With Stage 1 Hypertension: Effects on Blood Pressure, Vascular Compliance, and Endothelial Function
The Journal of Clinical Hypertension, 10/12/09
Relevance Score: 89%
Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: A retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension
Clinical Therapeutics, 10/23/09
Relevance Score: 85%
Today in Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
Hypertension Awareness, Treatment, and Control in Adults With CKD: Results From the Chronic Renal Insufficiency Cohort (CRIC) Study
American Journal of Kidney Diseases, 12/11/09
Hypertension in the Developing World: Challenges and Opportunities
American Journal of Kidney Diseases, 12/11/09
Characterization and treatment of resistant hypertension
Current Cardiology Reports, 12/11/09
Article Search
Sponsor